For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Praxis Precision Medicines, Inc.

USPTO Granted Patents = 28

EPO Patents = 6

Trademarks = 3

Forward Citations = 60

Loading Chart...

Loading Chart...

20 inventors (with patents filed for the assignee):

Gabriel Martinez Botella (23 out of 93 patents)

Kiran Reddy (20 out of 23 patents)

Andrew Mark Griffin (20 out of 32 patents)

4. Brian Edward Marron (19 out of 35 patents)

5. Nelson B Olivier (3 out of 3 patents)

6. Magnus Ronn (3 out of 11 patents)

7. Paul A Laskar (3 out of 4 patents)

8. Margaret S Lee (2 out of 8 patents)

9. Gabriel Maurice Belfort (2 out of 2 patents)

10. Sapna Makhija Garad (2 out of 2 patents)

11. Mahesh Padval (2 out of 2 patents)

12. Randall Wagner (2 out of 2 patents)

13. Carlos Loya (2 out of 2 patents)

14. Marion Wittmann (2 out of 2 patents)

15. Steven Petrou (1 out of 6 patents)

28 patents: Sort by Forward Citations

1. 12479844 - Ion channel modulators (2025-11-25),

2. 12404297 - Salts and crystal forms of GABA-positive allosteric modulator (2025-09-02),

3. 12344615 - Substituted pyridines as ion channel modulators (2025-07-01),

4. 12325711 - 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-α]pyrazine as an ion channel modulator (2025-06-10),

5. 12259378 - Dynamic clamps and methods of use thereof (2025-03-25),

6. 12145939 - Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators (2024-11-19),

7. 12077502 - Formulations of T-type calcium channel modulators and methods of use thereof (2024-09-03),

8. 12030881 - Ion channel modulators (2024-07-09),

9. 11918571 - Compounds and their methods of use (2024-03-05),

10. 11866439 - Ion channel modulators (2024-01-09),

11. 11773099 - Compounds and their methods of use (2023-10-03),

12. 11773088 - KCNT1 inhibitors and methods of use (2023-10-03),

13. 11767325 - Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators (2023-09-26),

14. 11731978 - 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator (2023-08-22),

15. 11731976 - 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator (2023-08-22),

Praxis Precision Medicines, Inc. is a biotechnology company focused on developing novel therapies for central nervous system (CNS) disorders. With a deep understanding of the underlying biology, Praxis aims to deliver precision medicine to patients suffering from rare genetic diseases, neuropsychiatric disorders, and neurodevelopmental disorders. Through innovative research and clinical development, the company strives to improve the lives of individuals affected by CNS disorders.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

28 Patents

#78 in Cambridge, MA

#685 in Massachusetts

#11,614 in US

#22,585 in the World

Cambridge, MA, United States of America

Praxis Precision Medicines, Inc.

Forward Citations = 60

20 inventors:

Gabriel Martinez Botella (23 out of 93 patents)

Kiran Reddy (20 out of 23 patents)

Andrew Mark Griffin (20 out of 32 patents)

4. Brian Edward Marron (19 out of 35 patents)

5. Nelson B Olivier (3 out of 3 patents)

Please report any incorrect information to support@idiyas.com

Loading…